As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The GENX Division of Hetero Healthcare is focused on delivering therapeutic solutions across cardiovascular and metabolic healthcare, supporting the management of chronic conditions that require consistent and long-term care. The division aims to provide healthcare professionals with dependable therapeutic options for managing cardiovascular risk factors and associated metabolic conditions, with a strong emphasis on improving overall patient well-being.
Its therapeutic portfolio addresses key areas such as hypertension, dyslipidaemia, cardiovascular risk management, diabetes and associated metabolic disorders. Through established therapies and combination treatment approaches, GENX supports the management of interconnected cardiometabolic conditions and helps healthcare professionals address the diverse clinical requirements of patients requiring ongoing treatment.
Backed by Hetero Healthcare’s commitment to quality, accessibility, innovation, and patient-centric care, the GENX Division continues to strengthen its presence in chronic disease management. With a focused portfolio and an understanding of evolving cardiometabolic healthcare needs, GENX strives to support effective clinical management, encourage continuity of care, and contribute to better long-term patient outcomes.
View by-
